Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.60 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.51 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.51 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.51 |
| ▸ | ADRB3 | P13945 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | BCHE | P06276 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CA3 | P07451 | 1/20 | 0.47 |
| ▸ | CA4 | P22748 | 1/20 | 0.47 |
| ▸ | CA6 | P23280 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1327171 | 1.00 | MAPT (0.60) | MAPTDNM1ADRB2ADRB1ADRB3 | |
| SCHEMBL17005472 | 1.00 | MAPT (0.60) | MAPTDNM1ADRB2ADRB1ADRB3 | |
| SCHEMBL23964580 | 0.85 | MAPT (0.50) | MAPTDNM1ADRB2ADRB1ADRB3 | |
| SCHEMBL2895685 | 0.83 | TSHR (0.45) | MAPTADRB2ADRB1ADRB3ALDH1A1 | |
| SCHEMBL2895680 | 0.83 | TSHR (0.45) | MAPTADRB2ADRB1ADRB3ALDH1A1 | |
| SCHEMBL12228656 | 0.83 | DNM1 (0.49) | DNM1ADRB2ADRB1ADRB3MEN1 | |
| SCHEMBL25868650 | 0.83 | HPGD (0.52) | DNM1ADRB2ADRB1ADRB3MEN1 | |
| SCHEMBL893963 | 0.83 | BCHE (0.63) | DNM1MEN1KMT2ABCHEALDH1A1 | |
| SCHEMBL11474774 | 0.82 | ADRB2 (0.71) | ADRB2ADRB1ADRB3MEN1KMT2A | |
| SCHEMBL23386838 | 0.82 | KDM4E (0.50) | DNM1ADRB2ADRB1ADRB3MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11767301-B2 | Bi-functional molecules to degrade circulating proteins | YALE UNIVERSITY (US) | 2023-09-26 | — | — | US | disclosed |
| US-11767301-B2 | Bi-functional molecules to degrade circulating proteins | YALE UNIVERSITY (US) | 2023-09-26 | — | — | US | disclosed |
| US-20210139436-A1 | Bi-functional Molecules to Degrade Circulating Proteins | YALE UNIVERSITY | 2021-05-13 | — | — | US | disclosed |
| CN-104640847-B | Novel Renin Inhibitors | 上海医药集团股份有限公司 | 2019-10-15 | — | — | CN | disclosed |
| EP-2350077-B1 | FUSED, SPIROCYCLIC HETEROAROMATIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | ENTASIS THERAPEUTICS LTD (GB) | 2016-01-27 | — | — | EP | disclosed |
| US-20150368266-A1 | CHEMICAL COMPOUNDS 542 | ENTASIS THERAPEUTICS INC. | 2015-12-24 | — | — | US | disclosed |
| US-9040528-B2 | Chemical compounds 542 | ASTRAZENECA AB (SE) | 2015-05-26 | — | — | US | disclosed |
| CN-104640847-A | Novel Renin Inhibitors | SHANGHAI PHARMACEUTICALS HOLDING CO LTD | 2015-05-20 | — | — | CN | disclosed |
| US-20140128371-A1 | CHEMICAL COMPOUNDS 542 | ASTRAZENECA AB (SE) | 2014-05-08 | — | — | US | disclosed |
| US-8658641-B2 | Fused, spirocyclic heteroaromatic compounds for the treatment of bacterial infections | ASTRAZENECA AB (SE) | 2014-02-25 | — | — | US | disclosed |
| US-20110245224-A1 | FUSED, SPIROCYCLIC HETEROAROMATIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | ASTRAZENECA AB (SE) | 2011-10-06 | — | — | US | disclosed |
| EP-2350077-A1 | FUSED, SPIROCYCLIC HETEROAROMATIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | AstraZeneca AB (SE) | 2011-08-03 | — | — | EP | disclosed |
| WO-2010043893-A1 | FUSED, SPIROCYCLIC HETEROAROMATIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | ASTRAZENECA AB (SE) | 2010-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11767301-B2 | Bi-functional molecules to degrade circulating proteins | MIF, ASGR1, FCGR2A | MAPT 4321/4885DNM1 2152/4885ADRB2 2665/4885 |
| US-20150368266-A1 | CHEMICAL COMPOUNDS 542 | MRPL21, CFTR, CYP3A43 | MAPT 2922/4885DNM1 2573/4885ADRB2 1319/4885 |
| US-20110245224-A1 | FUSED, SPIROCYCLIC HETEROAROMATIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | SDHB, SDHA, RORC | MAPT 4419/4885DNM1 836/4885ADRB2 1874/4885 |
| US-20210139436-A1 | Bi-functional Molecules to Degrade Circulating Proteins | MIF, ASGR1, FCGR2A | MAPT 4321/4885DNM1 2152/4885ADRB2 2665/4885 |
| US-20140128371-A1 | CHEMICAL COMPOUNDS 542 | MRPL21, CFTR, CYP3A43 | MAPT 2922/4885DNM1 2573/4885ADRB2 1319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.